Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting · NCT03145181 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 1 | 2026-09-25 | NCT03145181 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Research & Development, LLC | 188 |
13 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| CHRU Tours Hopital Bretonneau | Tours | France | 2 |
| City of Hope | Duarte | United States | 238 |
| Clinica Univ. de Navarra | Pamplona | Spain | 42 |
| Colorado Blood Cancer Institute | Denver | United States | 178 |
| Haematology Centre, R 51 | Stockholm | Sweden | 2 |
| Hosp Clinic de Barcelona | Barcelona | Spain | 37 |
| Hosp Clinico Univ de Salamanca | Salamanca | Spain | 34 |
| Hosp. Univ. Germans Trias I Pujol | Badalona | Spain | 28 |
| Hospices Civils de Lyon HCL | Lyon | France | 10 |
| Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects | New York | United States | 3 |
| Levine Cancer Institute | Charlotte | United States | 110 |
| University of Pennsylvania | Philadelphia | United States | 507 |
| VU Medisch Centrum | Amsterdam | Netherlands | 16 |